Syndax Pharmaceuticals (SNDX) News Today

Syndax Pharmaceuticals (NASDAQ:SNDX) saw its share price rise today following strong second-quarter results, multiple analyst price-target increases and upbeat guidance for its lead oncology products.

• Positive Sentiment: Syndax beat Q2 EPS estimates, reporting a loss of $0.83 per share versus consensus of a $0.99 loss, and delivered revenue of $37.96 million, up 984.5% year-over-year. Syndax Pharmaceuticals (NASDAQ:SNDX) Announces Earnings Results
• Positive Sentiment: Syndax’s stock jumped after the Q2 beat and Citi flagged potential upside catalysts ahead. Syndax jumps after Q2 beat; Citi issues upside catalyst watch
• Positive Sentiment: Citi lifted its price target on SNDX from $46.00 to $51.00 and maintained a “buy” rating, implying over 300% upside. Benzinga
• Positive Sentiment: BTIG raised its price target from $43.00 to $56.00 with a “buy” rating, suggesting roughly 345% upside. Benzinga
• Positive Sentiment: A Seeking Alpha analysis highlighted management’s increased long-term market projections, targeting $10 billion in peak sales for Revuforj and Niktimvo combined, with profitability potentially arriving by FY 2028. Syndax Pharmaceuticals: The Story Brightens
• Positive Sentiment: Q2 revenue surged 986%, driven by strong uptake of Revuforj. Syndax (SNDX) Q2 Revenue Jumps 986%
• Positive Sentiment: Zacks noted the Q2 loss of $0.83 beat consensus revenue estimates, reflecting strong top-line growth. Zacks
• Positive Sentiment: Revuforj net revenue grew 43% sequentially to $28.6 million in Q2, per the company’s business update. GlobeNewswire
• Neutral Sentiment: Syndax published the full Q2 earnings call transcript detailing management’s discussion of results and pipeline progress. Syndax Q2 2025 Earnings Call Transcript
• Neutral Sentiment: The company also released its Q2 earnings presentation slides. Syndax Q2 Presentation